- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03787836
Improving Individual Glycemic Response With Exercise Intensity (INTENSITY)
Study Overview
Status
Intervention / Treatment
Detailed Description
Exercise can effectively slow the progression towards Type 2 diabetes (T2D). However, data suggest large interindividual variability exists in glycemic response to exercise, resulting in a subset of individuals known as exercise non-responders (NRs). Emerging research proposes that altering the parameters of an exercise intervention to provide a sufficient stimulus can elicit a response in those previously identified as NRs. To date, no research has attempted to rescue previously classified NRs based on glycemic outcomes by altering the parameters of an exercise intervention.
This study will implement an exercise program targeted at achieving the Canadian Physical Activity Guidelines, and calculate the number of NRs. We will then evaluate if increasing the intensity of exercise will elicit response to the treatment in the NRs.
Sixty adults living with prediabetes or T2D will be recruited into one of a control group, or an exercise group. The exercising participants will begin a 16-week exercise intervention, targeted at achieving 150 minutes of moderate to vigorous intensity (equating to 4.5 METs) aerobic physical activity per week. Following the 16-week exercise program, participants will be randomized into two groups, each completing an additional 12 weeks of exercise. The first will maintain the same time and intensity, while the other will complete the 150 minutes per week at an intensity equal to 6.0 METs. Randomization will occur in blocks in order to ensure an equal number of NRs in each group.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 5A3
- University of New Brunswick
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Community-dwelling adults aged 19 years or older.
- Currently living with prediabetes or T2DM as diagnosed by a physician and confirmed by an HbA1c value of 5.7% or above, as verified by duplicate testing.
- Not currently partaking in a self-reported regular physical activity regimen, defined as consistent participation in running or jogging activity, attending physical activity or exercise classes on a weekly basis, or averaging 10,000 steps per day or more over the course of 7 days.
Exclusion criteria:
- Self reported as currently diagnosed as having, or being treated for, low iron concentrations or anemia.
- Diagnosed with any red blood cell altering condition.
- Currently living with any cardiovascular disease which would impact the ability to safely participate in exercise training.
- Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track exercise intensity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Controls
The primary purpose of the control participants are to provide a measure of variability.
They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
|
|
Experimental: Exercisers (Maintained)
The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
|
Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing. Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs). Duration: Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week Week 17: Physiological Testing Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity. |
Experimental: Exercisers (Increased Intensity)
The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
|
Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing. Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs). Duration: Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week Week 17: Physiological Testing Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise responders following initial program
Time Frame: Week 17
|
The number of responders to the original 16-week exercise program, based on improvement in glycated hemoglobin
|
Week 17
|
Exercise responders following additional exercise program
Time Frame: Week 30
|
The number of responders following the additional 12-week exercise program, based on improvement in glycated hemoglobin
|
Week 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sex
Time Frame: Baseline
|
Participant self-reported biological sex
|
Baseline
|
Family history of cardiovascular disease
Time Frame: Baseline
|
Self-reported family history of cardiovascular disease
|
Baseline
|
Family history of cardiometabolic disease
Time Frame: Baseline
|
Self-reported family history of cardiometabolic disease
|
Baseline
|
Current medication use
Time Frame: Baseline
|
Record of quantity and dose of current medications
|
Baseline
|
Physical activity patterns
Time Frame: Baseline
|
Participant self-reported physical activity patterns and daily step counts over a 7-day period.
|
Baseline
|
Daily step count
Time Frame: Baseline
|
Daily step count as recorded over a 7-day period
|
Baseline
|
Body mass
Time Frame: Baseline, week 17 and week 30
|
Body mass (kilograms)
|
Baseline, week 17 and week 30
|
Height
Time Frame: Baseline, week 17 and week 30
|
Height (centimetres)
|
Baseline, week 17 and week 30
|
Waist circumference
Time Frame: Baseline, week 17 and week 30
|
Waist circumference (cm)
|
Baseline, week 17 and week 30
|
Fat mass
Time Frame: Baseline, week 17 and week 30
|
Fat mass (kg)
|
Baseline, week 17 and week 30
|
Fat free mass
Time Frame: Baseline, week 17 and week 30
|
Fat free mass (kg)
|
Baseline, week 17 and week 30
|
Cardiorespiratory fitness
Time Frame: Baseline, week 17 and week 30
|
VO2 peak
|
Baseline, week 17 and week 30
|
Body mass index
Time Frame: Baseline, week 17, week 30
|
Weight (kilograms) and height (measured in centimetres and converted to metres) will be combined to report body mass index in kg/m^2
|
Baseline, week 17, week 30
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Montero D, Lundby C. Refuting the myth of non-response to exercise training: 'non-responders' do respond to higher dose of training. J Physiol. 2017 Jun 1;595(11):3377-3387. doi: 10.1113/JP273480. Epub 2017 May 14. Erratum In: J Physiol. 2018 Apr 1;596(7):1311.
- Hecksteden A, Pitsch W, Rosenberger F, Meyer T. Repeated testing for the assessment of individual response to exercise training. J Appl Physiol (1985). 2018 Jun 1;124(6):1567-1579. doi: 10.1152/japplphysiol.00896.2017. Epub 2018 Jan 11.
- de Lannoy L, Clarke J, Stotz PJ, Ross R. Effects of intensity and amount of exercise on measures of insulin and glucose: Analysis of inter-individual variability. PLoS One. 2017 May 11;12(5):e0177095. doi: 10.1371/journal.pone.0177095. eCollection 2017.
- Hrubeniuk TJ, Bouchard DR, Gurd BJ, Senechal M. Can non-responders be 'rescued' by increasing exercise intensity? A quasi-experimental trial of individual responses among humans living with pre-diabetes or type 2 diabetes mellitus in Canada. BMJ Open. 2021 Apr 5;11(4):e044478. doi: 10.1136/bmjopen-2020-044478.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-168
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Maintained Exercise
-
Rigshospitalet, DenmarkWithdrawnAnesthesia | Peripheral Arterial DiseasesDenmark
-
Davison, James, D.O.UnknownAnemia | Iron Deficiency
-
Genzyme, a Sanofi CompanyTerminatedNon-Hodgkins LymphomaUnited States
-
CABYCGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaTerminatedGraft Versus Host DiseaseSpain
-
German CLL Study GroupCompleted
-
Jordi Gol i Gurina FoundationUnknown
-
University of British ColumbiaGenzyme, a Sanofi CompanyCompletedRelapsing Remitting Multiple SclerosisCanada
-
Affiliated Cancer Hospital & Institute of Guangzhou...Unknown
-
University Hospital, Gentofte, CopenhagenCompleted